Valuation: Black Diamond Therapeutics, Inc.

Market Cap 106M 92.79M 85.65M 79.9M 151M 10.02B 153M 1.03B 399M 4.95B 398M 389M 17.23B P/E 2026 *
-2.86x
P/E 2027 * -1.84x
Enterprise Value 106M 92.79M 85.65M 79.9M 151M 10.02B 153M 1.03B 399M 4.95B 398M 389M 17.23B EV / Sales 2026 *
19.1x
EV / Sales 2027 * -
Free-Float
99.35%
Yield 2026 *
-
Yield 2027 * -
1 day+5.71%
1 week+14.91%
1 month-16.67%
3 months-13.15%
6 months-23.87%
Current year-23.87%
1 week 1.68
Extreme 1.68
1.89
1 month 1.6
Extreme 1.6
2.27
Current year 1.6
Extreme 1.6
3.97
1 year 1.6
Extreme 1.6
4.94
3 years 1.2
Extreme 1.195
7.66
5 years 1.18
Extreme 1.18
12.48
10 years 1.18
Extreme 1.18
46.25
Manager TitleAgeSince
Chief Executive Officer 62 16/09/2023
Chief Tech/Sci/R&D Officer 51 11/08/2021
Director of Finance/CFO 41 07/10/2024
Director TitleAgeSince
Director/Board Member 61 01/03/2017
Director/Board Member 47 01/12/2019
Director/Board Member 50 01/12/2018
Date Insider Type Main position Quantity % Market Cap.
26/06Free

Director

40,000 0.0698%
26/06Free

Director

40,000 0.0698%
26/06Free

Director

40,000 0.0698%
Change 5-day change 1-year change 3-year change Capi.($)
+5.71%+14.91%-25.40%-63.37% 106M
+0.39%+8.82%+71.31%+133.14% 57.65B
-1.32%+17.12%+79.02%+99.82% 55.14B
-1.28%+2.68%-12.60%-13.79% 23.53B
+1.79%+4.38%+5.94%+405.31% 23.11B
-1.93%+11.11%+34.89%-7.86% 18.14B
+1.62%+6.86%+38.68%-29.70% 16.84B
+0.24%+5.98%+23.45%+184.72% 13.68B
+0.14%+9.60%+33.31% - 12.97B
+1.83%+4.58%+77.42%+132.45% 12.38B
Average +0.79%+6.60%+32.60%+93.42% 23.35B
Weighted average by Cap. -0.01%+4.88%+48.39%+116.69%

Financials

2026 *2027 *
Net sales 5.56M 4.86M 4.49M 4.19M 7.89M 525M 8.03M 53.84M 20.9M 259M 20.87M 20.41M 903M -
Net income -40.47M -35.43M -32.7M -30.5M -57.48M -3.83B -58.5M -392M -152M -1.89B -152M -149M -6.58B -70.04M -61.31M -56.6M -52.79M -99.47M -6.62B -101M -679M -264M -3.27B -263M -257M -11.39B
Net Debt - -
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
21
Date Price Change Volume
30/06/26 USD 1.850 +5.71% 1,883,436
29/06/26 USD 1.750 +2.34% 1,154,453
26/06/26 USD 1.710 +0.59% 8,578,830
25/06/26 USD 1.700 -8.60% 1,932,360
24/06/26 USD 1.860 +15.53% 2,871,541
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.850USD
Average target price
9.857USD
Spread / Average Target
+432.82%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BDTX Stock